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Abstract
Background:  Because cells progressing to cancer must proliferate, marker proteins specific to
proliferating cells may permit detection of premalignant lesions. Here we compared the sensitivities
of a classic proliferation marker, Ki-67, with a new proliferation marker, MCM2, in 41 bronchial
biopsy specimens representing normal mucosa, metaplasia, dysplasia, and carcinoma in situ.
Methods:  Parallel sections were stained with antibodies against MCM2 and Ki-67, and the
frequencies of staining were independently measured by two investigators. Differences were
evaluated statistically using the two-sided correlated samples t-test and Wilcoxon rank sum test.
Results:  For each of the 41 specimens, the average frequency of staining by anti-MCM2 (39%) was
significantly (p < 0.001) greater than by anti-Ki-67 (16%). In metaplastic lesions anti-MCM2
frequently detected cells near the epithelial surface, while anti-Ki-67 did not.
Conclusions:  We conclude that MCM2 is detectable in 2-3 times more proliferating premalignant
lung cells than is Ki-67. The promise of MCM2 as a sensitive marker for premalignant lung cells is
enhanced by the fact that it is present in cells at the surface of metaplastic lung lesions, which are
more likely to be exfoliated into sputum. Future studies will determine if use of anti-MCM2 makes
possible sufficiently early detection to significantly enhance lung cancer survival rates.
Introduction
The 5-year survival rate for patients with lung cancer is
approximately 15%, and it has changed only marginally
in the last 30 years [1]. Tumor stage is the most signifi-
cant prognostic parameter for 5-year survival, but even
patients with non-small cell lung cancer (non-SCLC) in
pathologic stage IA disease (a tumor of less than 3 cm di-
ameter located in one lobe of the lung and more than 2
cm from the carina without visceral pleural involvement,
atelectasis, or pneumonitis, and absence of metastatic
spread to regional lymph nodes) have a 33% chance of
recurrence within 5 years after complete surgical resec-
tion (lobectomy with mediastinal lymph node dissec-
tion) [2]. In this group of patients, the tumor most
frequently recurs at distant sites, including the bone, liv-
er, adrenal glands, and brain [3], and the size of the pri-
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mary tumor does not appear to impact on survival [4].
This suggests that even small and seemingly resectable
lung cancers metastasize early. Data from randomized
screening trials for lung cancer corroborate this observa-
tion. In these studies, more cancers were detected in re-
sectable stages, and 5-year survival rates were higher in
the screened population compared to the control popula-
tion, but mortality rates (total death rate independent of
time) from lung cancer were equal in both groups [5].
For this reason, it is important to develop methods that
will permit facile detection of bronchial mucosal abnor-
malities that are precursors for lung cancer before sys-
temic shedding of tumor cells occurs. Such precursor
lesions can be detected by sputum cytology and by bron-
choscopy in large airways accessible by endoscopy. They
include metaplasia, dysplasia, and carcinoma in situ
(CIS), which are thought to represent progressive histo-
logic correlates of carcinogenesis for squamous cell car-
cinoma [6].
Current data suggest that 23% of current and former
smokers have metaplastic lesions, and 2% have dysplas-
tic lesions [7]. However, not all such lesions progress to
lung cancer. For instance, smoking cessation, which can
be viewed as a form of active intervention, appears to re-
sult in a decrease of metaplasia rates from 27% in active
smokers to 7% in former smokers [7]. It is estimated that
approximately 50% of CIS will progress to invasive can-
cer over a 6-month time period [8]. However, of 9 pa-
tients followed by regular bronchoscopy at 6-month time
intervals, 4 developed lung cancer at sites that had previ-
ously been biopsied and interpreted as normal bronchial
epithelium [8]. These results raise several important
questions: A) Are there determinants in premalignant le-
sions that predict outcome, i.e., progression versus re-
gression? B) Are there determinants in morphologically
normal bronchial mucosa that predict outcome? C) Can
lung cancer arise directly from normal bronchial mucosa
or are histopathologic intermediates required?
To address these questions, one promising approach
would be the development of specific immunohisto-
chemical markers capable of improving the sensitivity
and reliability of methods currently employed to detect
precursor lesions in histologic and cytologic specimens
[9, 10]. Because proliferation is a requirement for lung
cancer development, markers specific for cell prolifera-
tion are expected to prove useful.
Two proliferation markers, proliferating cell nuclear an-
tigen (PCNA) and Ki-67, have been extensively studied in
this context. PCNA is a homotrimeric protein that binds
tightly to DNA and to proteins involved in DNA replica-
tion and repair. It is essential for DNA replication and is
found in all proliferating cells. However, because PCNA
is also essential for several types of DNA repair, it may be
present in non-proliferating cells [11, 12]. Ki-67 is an
epitope of a nuclear protein recognized by the MIB-1
monoclonal antibody. The protein is frequently ex-
pressed throughout the cell cycle of proliferating cells,
and it has not been detected in non-proliferating cells.
During interphase, Ki-67 is located primarily in nucleo-
lar and peri-nucleolar regions, and it appears to be asso-
ciated with condensed chromatin [13]. The function of
the Ki-67 protein is still unknown [14], however, it ap-
pears to be required for cells to progress through the cell
cycle [15, 16]. Immunohistochemical studies with PCNA
and Ki-67 indicate that, in at least some cases, increased
lung tumor staining for these markers correlates with de-
creased survival [17,18,19,20]. These proliferation mark-
ers can also be detected in premalignant lesions of the
lung [21,22,23,24].
In this report, we describe the results of our comparison
of one of these classic proliferation markers, Ki-67, with
a new proliferation marker, MCM2 [25]. MCM2 is one of
six members of the minichromosome maintenance
(MCM) protein family. These serve as components of "li-
censing factor," which is essential for initiation of DNA
replication and for limiting replication to one round per
cell cycle [26, 27]. The MCM proteins are also associated
with replication forks and are likely to stimulate the un-
winding of the parental DNA strands at these forks [28].
We previously demonstrated [25] that, in normal tissues,
MCM2 is detectable only in proliferating cells. Not sur-
prisingly, it is also present in a high proportion of cancer
cells. Our results showed a higher proportion of positive-
ly stained cells in premalignant breast lesions than with
either PCNA or Ki-67 [25]. Others have reported similar
results for MCM family proteins compared with Ki-67
and PCNA for detection of a variety of premalignant cell
types [29, 30], but a comparison of MCM proteins with
Ki-67 or PCNA as markers for premalignant lung lesions
has not previously been reported.
Methods
Study population
MCM2 and Ki-67 expression in bronchial biopsy speci-
mens from patients at risk for lung cancer or with sus-
pected lung cancer were studied by
immunohistochemistry (IHC). We reviewed all patholo-
gy specimens from 106 patients that had undergone
bronchoscopy with standard white light and laser-in-
duced fluorescence at Roswell Park Cancer Institute
from March 1998 to March 2000. Fourteen of these 106
patients were selected for further analysis based on the
presence of abnormal morphology and the availability of
multiple specimen blocks (4-17 per patient) for investi-
gations. Of these 14 patients, the highest degree of ab-BMC Cancer (2001) 1:6 http://www.biomedcentral.com/1471-2407/1/6
normality in 4 was metaplasia, in 4 dysplasia, in 3 CIS, in
1 invasive squamous cell carcinoma, and in 2 invasive ad-
enocarcinoma. Five of these patients were Caucasian
women, 1 was an African-American man, and 8 were
Caucasian men. All were active or former smokers.
Sample preparation and selection
From each specimen block, 5 serial 4-µm sections were
cut and placed on charged glass slides. Sections 1-4 were
used for IHC, and section 5 was stained with hematoxy-
lin and eosin. This latter section was reviewed and com-
pared with the original slide used for diagnostic
purposes. In 41 specimens, the morphology was compa-
rable between the original slide and slide 5. These 41
specimens were used for IHC analysis and included mor-
phologically normal bronchial mucosa, metaplasia, dys-
plasia, and CIS (see Table 1 for the numbers of specimens
with normal and abnormal morphology).
Immunohistochemistry
Sections were stained with polyclonal rabbit antibodies
raised and affinity-purified against the N-terminal por-
tion of MCM2 [25]. Parallel sections were stained with
the MIB-1 mouse monoclonal antibody against Ki-67
(DAKO, Carpinteria, California). IHC was performed as
described earlier [25]. Briefly, sections were deparaffin-
ized, and those to be stained with Ki-67 were subjected to
microwave antigen retrieval in citrate buffer for 10 min-
utes, twice. Antigen retrieval was not required for
MCM2. MIB-1 was used at a dilution of 1:50. The MCM2
antibody was used at a dilution of 1:500. The avidin-bi-
otin detection method was employed on a Ventana Auto-
mated System (Tucson, Arizona). An irrelevant rabbit
antiserum served as a negative control. Percentage, in-
tensity, and distribution of stained cells were analyzed
and scored for each antibody independently by two of the
authors (DFT, JAH) with similar results.
Statistical Analysis
The percent of cells stained for each sample was estimat-
ed as a continuous number ranging from 0 to 100. The
staining intensity was categorically coded as 0 (absent),
1 (weak), 2 (moderate), or 3 (strong). The average of both
the percent of cells stained and staining intensity was
calculated for each type of specimen (normal mucosa,
metaplasia, dysplasia, CIS). To test for differences be-
tween the staining characteristics of MCM2 and Ki-67
both the parametric paired samples t-test and the non-
parametric Wilcoxon rank-sum test were performed. To
test for differences across specimen classes (normal mu-
cosa, metaplasia, dysplasia and CIS) for each stain (Ki-67
or MCM2), the analysis of variance method as well as the
non-parametric Kruskal-Wallis tests were used. To test
specifically for differences between dysplasia and CIS for
each stain, the independent samples t-test and the
Mann-Whitney tests were performed. Both parametric
and non-parametric tests were used because the distri-
butional assumptions required for parametric testing
may not be satisfied in all cases. All statistical tests as-
sumed a two-sided alternative with a 5% level of signifi-
cance.
Results
In normal bronchial mucosa, antibodies against both
proteins, MCM2 and Ki-67, generated similar patterns:
some cells in the basal and parabasal layer of the bron-
chial epithelium displayed immunoreactivity (Fig. 1).
The proportion of cells staining for MCM2 was signifi-
cantly (p < 0.02) greater than for Ki-67 (Table 1). In both
cases, the intensity of nuclear staining was variable.
Table 1: Percentage and intensity of staining for MCM2 and Ki-67 in normal bronchial mucosa and premalignant lesions
Type of Number of % Cells Positive % Cells Positive Mean Mean
Specimen Specimens for MCM2 for Ki-67 Intensity for Intensity
Mean (Range) Mean (Range) MCM2a for Ki-67a
Normal Mucosa 7 11b,e (5-20) 3b,f (1-5) 1.6i (1.0-2.0) 1.6i (1.0-2.5)
Metaplasia 21 39c,e (7-90) 14c,f (1-60) 2.3i (1.0-3.0) 2.3i (1.0-3.0)
Dysplasia 7 64d,e,g (40-100) 34d,f (7-40) 2.6i (2.0-3.0) 2.8i (2.0-3.0)
CIS 6 39e,g (5-60) 17f,h (3-60) 2.4i (2.0-3.0) 2.3i (1.0-3.0)
Combined data 41 39c(5-100) 16c (1-60) 2.2 (1.0 - 3.0) 2.3 (1.0-3.0)
a The intensity of stain ranges from 0 (absent) to 3 (strong). b p-value < 0.016 for the paired difference t-test and Wilcoxon sign rank test. c p-value 
< 0.001 for the paired difference t-test and Wilcoxon sign rank test. d p-value < 0.034 for the paired difference t-test and <0.063 for the Wilcoxon 
sign-rank test. e p-value <0.010 for the ANOVA and Kruskal-Wallis tests of differences in MCM2 category means. f p-value <0.001 for the ANOVA 
and Kruskal-Wallis tests of differences in Ki-67 category means. g p-value <0.080 for the independent samples t-test between dysplasia and CIS within 
MCM2. h p-value <0.117 for the independent samples t-test between dysplasia and CIS within Ki67. i p-value <0.004 for the ANOVA and Kruskal-
Wallis tests of differences in MCM2 and Ki-67 category means.BMC Cancer (2001) 1:6 http://www.biomedcentral.com/1471-2407/1/6
Figure 1
Comparisons of staining by anti-MCM2 and anti-Ki-67 in parallel sections of normal bronchial mucosa and pre-
malignant lung lesions. All objective lens magnifications were 20×  except for the upper panels of normal bronchial mucosa
and metaplasia, which were 40× .
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In premalignant lesions, evaluation of the staining by the
two antibodies (Table 1) revealed significantly (p <
0.001) more frequent staining of nuclei within metaplas-
tic lesions by antibodies against MCM2 than by antibod-
ies against Ki-67. We also noticed that, in metaplasia,
anti-MCM2 frequently stained both basal cells and cells
throughout the entire thickness of the epithelium, while
anti-Ki-67 primarily stained basal cells and cells in the
lower half of the epithelium (Fig. 1, lower of the two
"metaplasia" panels). Although the number of samples of
dysplasia and CIS was too low to permit statistical evalu-
ation of the differences between the two antibodies, we
noticed that in every case of dysplasia or CIS, the fre-
quency of cells stained by anti-MCM2 was as high or
higher than the frequency of staining by anti-Ki-67. In
fact, the same relationship was evident in the normal
mucosa and metaplasia samples. Consequently, when
the data for all 41 samples were combined, the difference
in staining frequency between anti-MCM2 and anti-Ki-
67 was highly significant (p < 0.001; Table 1).
We observed variable staining in premalignant lesions.
In many cases, within single lesions some regions
stained while others did not, and the intensity of staining
was variable from region to region and from cell to cell
within regions. The level of variability was similar for
both markers (Fig. 1).
In the progression from normal mucosa to metaplasia to
dysplasia, the results obtained with both antibodies sug-
gested differences in staining frequency and intensity.
For both antibodies, the mean percentages of cells
stained and staining intensity were different across spec-
imen categories (all p-values <0.010) and increased
from normal mucosa to metaplasia and from metaplasia
to dysplasia. Although the sample numbers are too low to
draw a firm conclusion, the data suggest a possible de-
crease in staining frequency by both antibodies in the
transition from dysplasia to CIS (p = 0.117 for Ki-67 and
p = 0.080 for MCM2) (Table 1).
No significant differences were detected between the av-
erage stain intensities produced by the two antibodies
(Fig. 1; Table 1).
Discussion
This is the first comparison of MCM2 and Ki-67 expres-
sion in premalignant lesions of the human lung, and it
showed that MCM2 was expressed in a greater percent-
age of cells in normal mucosa and in premalignant le-
sions than Ki-67. The proportion of cells stained for
MCM2 ranged from 5% to 100% and for Ki-67 from 1% to
60% (Table 1). The average percentage of cells stained for
MCM2 (11-64%) was higher than that for Ki-67 (3-34%).
Statistical analyses of the frequencies of positively
stained cells were done with the paired samples t-test
and the Wilcoxon sign rank test. Both tests showed a
striking difference (p < 0.001) in immunoreactivity be-
tween these markers across all 41 samples. This finding
suggests that MCM2 may prove to be a more sensitive in-
termediate marker for lung cancer risk than Ki-67.
However, there are several caveats to the use of MCM2
for assessing lung cancer risk. Most importantly, the
ability of cells to proliferate, even though a hallmark of
malignancy, is also a component of inflammation and
healing. Thus, metaplastic lesions are frequently associ-
ated with chronic inflammation as exemplified by the
presence of such lesions in 27% of current smokers but
only 7% of former smokers [7]. Furthermore, even high-
grade dysplasia does not necessarily lead to invasive can-
cer [8]. The fact that anti-MCM2 more frequently stains
metaplastic cells at the epithelial surface suggests that it
is more likely than anti-Ki-67 to detect exfoliated prolif-
erating epithelial cells in cytological specimens such as
sputum. However, this presumably higher sensitivity for
premalignant cells could be accompanied by an unac-
ceptably low specificity. Therefore, it is important to as-
sess the positive predictive value of both markers, MCM2
and Ki-67, for lung cancer risk in cytologic and histologic
specimens from a defined population at risk for this dis-
ease in a prospective study.
Second, there has been a shift in the predominant type of
lung cancer from squamous cell carcinoma to adenocar-
cinoma in the United States over the past twenty years
[4, 31]. Since adenocarcinomas predominantly arise in
the periphery of the lung and less frequently in the larger
and more easily accessible airways, the utility of assess-
ing morphological, molecular, and proliferative changes
in these larger airways may be called into question. Dur-
ing the 1970s three randomized lung cancer screening
trials were conducted in the US, and each of these trials
used sputum cytology as one of the means to detect lung
cancer at an early stage [32,33,34]. Aside from the major
finding that screening did not reduce lung cancer mortal-
ity, several other important facts were uncovered. These
included the findings that lung cancers detected by spu-
tum cytology only, compared to chest X-ray only, had a
higher rate of complete resectability (83% vs. 62%) and a
higher 5-year survival rate (80% vs. 40%) [33]; that ap-
proximately one-third of the cancers detected by sputum
cytology were adenocarcinomas and two-thirds were sq-
uamous cell carcinomas [32]; that sputum cytology de-
tected 36% of all incident cases of lung cancer (excluding
interval cases) [32]; and that sputum cytology detected
6/40 adenocarcinomas [32]. It can thus be concluded
that cytological examination of sputum specimens is able
to detect adenocarcinomas at an early stage albeit with
low sensitivity (15%). Staining of sputum specimens forBMC Cancer (2001) 1:6 http://www.biomedcentral.com/1471-2407/1/6
proliferation markers, such as MCM2 and Ki-67, may in-
crease that sensitivity by focusing the pathologist's atten-
tion on proliferating cells. In addition to its potential for
detecting frank malignancy, staining for proliferation
markers may also provide an estimate of the frequency of
potentially precancerous conditions (metaplasia and
dysplasia) in the patient's airways. This estimate may be
helpful for determining whether to initiate other more
costly evaluations for lung cancer detection.
Third, since MCM2 and Ki-67 are both markers of cellu-
lar proliferation and required for cell cycle progression
[15, 16, 26,27,28], the fact that anti-MCM2 stained a
larger number of cells than anti-Ki-67 in every specimen
examined suggests that Ki-67 may be expressed during a
shorter interval of the cell cycle than MCM2. MCM2 is
present throughout the cell cycle [35], while Ki-67 is pre-
dominantly expressed during S, G2 and M phase. Varia-
bility of cell cycle time in mammalian cells is largely a
result of differences in the duration of G1 phase. Thus,
specimens that consist of a relatively slow growing pop-
ulation of cells and consequently a higher proportion of
cells in G1 phase would show staining of more cells with
MCM2 than Ki-67.  Conversely, specimens with cells di-
viding at a high rate would show staining of near equal
numbers of cells for MCM2 and Ki-67. Thus it is likely
that staining for both, MCM2 and Ki-67, will provide in-
formation about cell cycle distribution and possibly
growth dynamics not obtainable by staining for either
marker alone.
Finally, the data presented on MCM2 expression by IHC
were obtained with affinity-purified polyclonal rabbit
antibodies. The supply of these purified antibodies is
limited, and their use for MCM2 immunostaining is
therefore not uniformly available. Although additional
polyclonal antibody preparations can be generated by
immunizing more rabbits, the best solution would be the
commercial availability of specific MCM2 monoclonal
antibodies. Fortunately, several of these are now availa-
ble and useful for Western blotting and staining of frozen
sections. The utility of these antibodies for IHC in paraf-
fin-embedded specimens is being investigated.
Conclusion
We have confirmed that polyclonal anti-MCM2 antibod-
ies provide consistent, reliable staining in routinely fixed
tissues without a requirement for antigen retrieval. Re-
sults obtained are easy to interpret, since there is a strik-
ing difference between normal bronchoepithelium and
premalignant lesions. Thus MCM2 is an easy-to-use
marker, which has great potential for assessment of pro-
gression and regression of morphologically abnormal le-
sions in future primary lung cancer prevention studies
and for the early detection of lung cancer in screening
studies.
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